Last reviewed · How we verify
Adult differentiated autologous T-cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Adult differentiated autologous T-cells (Adult differentiated autologous T-cells) — Sara V. Latorre.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adult differentiated autologous T-cells TARGET | Adult differentiated autologous T-cells | Sara V. Latorre | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adult differentiated autologous T-cells CI watch — RSS
- Adult differentiated autologous T-cells CI watch — Atom
- Adult differentiated autologous T-cells CI watch — JSON
- Adult differentiated autologous T-cells alone — RSS
Cite this brief
Drug Landscape (2026). Adult differentiated autologous T-cells — Competitive Intelligence Brief. https://druglandscape.com/ci/adult-differentiated-autologous-t-cells. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab